-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

Piper Sandler Maintains Overweight on Century Therapeutics, Lowers Price Target to $14

Benzinga · 01/06/2023 06:43
Piper Sandler analyst Edward Tenthoff maintains Century Therapeutics (NASDAQ:IPSC) with a Overweight and lowers the price target from $24 to $14.